COMPANY:

Elypta

"Elypta...announced the publication of a scientific study in the peer-reviewed journal JCO Precision Oncology using its GAGome-based liquid biopsy to predict and monitor responses of patients with Metastatic Renal Cell Carcinoma (mRCC) treated with tyrosine kinase inhibitors." "

"Swedish cancer detection company Elypta today announces the publication of groundbreaking research conducted at Chalmers University of Technology by Elypta founders Prof. Jens Nielsen and Dr. Francesco Gatto, showcasing the multi-cancer early detection (MCED) potential of glycosaminoglycans as biomarkers of tumor metabolism...Researchers developed a test based on the measurement of free glycosaminoglycan profiles in plasma and urine using Elypta’s MIRAM kit and samples from 979 participants diagnosed with 14 different cancer types, including types difficult to detect with other methods such as brain tumors and kidney cancer, and healthy subjects."

"Elypta...announced the raise of $21 million in a series A financing round led by Bonnier Ventures..The company will use the capital to develop and validate blood and urine tests for Multi-Cancer Early Detection (MCED) in adults with no symptoms of cancer and for detection of recurrence in kidney cancer patients. The tests are based on the exhaustive profiling of human glycosaminoglycans – also known as the GAGome – as biomarkers of cancer metabolism, an approach pioneered by Elypta based on research performed at Chalmers University of Technology by founders Francesco Gatto and Jens Nielsen."

"Swedish molecular diagnostics company Elypta today announced the launch of its second clinical study intended to validate the diagnostic performance of GAGomes – the complete profile of human glycosaminoglycans – as metabolic biomarkers for Multi-Cancer Early Detection (MCED). This study, LEVANTIS-0093A (LEV93A), aims to detect any-type cancer in adults at high risk of developing cancer due to significant smoking history."

"Swedish molecular diagnostics company Elypta announces today the launch of the clinical study LEVANTIS-0087A (LEV87A), intended to validate the diagnostic performance of GAGomes – the complete profile of human glycosaminoglycans – as metabolic biomarkers for Multi-Cancer Early Detection (MCED). The study aims to detect any-type cancer in adults who show no symptoms or have any recent history of cancer."

"Swedish molecular diagnostics company Elypta announces...the activation of the 26th recruiting site for the AURORAX-0087A (AUR87A) study, making it the largest diagnostics study ever of the most common type of kidney cancer. AUR87A is intended to validate Elypta’s metabolism-based liquid biopsy platform for the detection of recurrence after surgery in clear cell renal cell carcinoma (ccRCC)."

"Elypta announces the enrollment of the first patient in the newly initiated AURORAX-0093A (AUR93A) study. AUR93A is intended to explore Elypta’s metabolism-based liquid biopsy platform for the prognosis of muscle-invasive bladder cancer (MIBC) before neo-adjuvant chemotherapy."